Hemoglobin vesicles ameriolate allograft airway rejection

Research Project

Project/Area Number	24791470
Research Category	Grant-in-Aid for Young Scientists (B)
Allocation Type	Multi-year Fund
Research Field	Thoracic surgery
Research Institution	Keio University
Principal Investigator	KASEDA Kaoru 慶應義塾大学, 医学部, 助教 (70624435)
Project Period (FY)	2012-04-01 – 2014-03-31
Project Status	Completed (Fiscal Year 2013)
Budget Amount *help	¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000) Fiscal Year 2013: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000) Fiscal Year 2012: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Keywords	肺移植
Research Abstract	Acute rejection after lung transplantation is the main risk factor for the development of bronchiolitis obliterans (BO). Hemoglobin-vesicles (HbV) have been developed for use as artificial oxygen carriers and this can provide anti-inflammatory effects and may serve to limit tissue injury in airway transplant. Here, we tested the ability of HbV to prevent airway rejection. Tracheal grafts from BALB/c or C57BL/6 were transplanted to C57BL/6 recipients. Experimental groups were treated with HbV. Histopathological evaluation of luminal obliteration was blindly reviewed. Immunohistochemistry and real-time RT-PCR analyses were performed. Allografts treated with HbV revealed a reduction of thickening in epithelial and subepithelial airway layers at day 7 in orthotopic trachea transplantation model compared with allografts treated with vehicle. There was also a concordant decrease in CD3+ lymphocytes and macrophages in HbV treated allografts.